Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock

$14.63

1.39% yesterday

NYSE, Aug 12, 10:00 pm CET

ISIN

US8740602052

Symbol

TAK

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock price

$14.63

-4.06 21.72% 5Y

NYSE, Closing price Tue, Aug 12 2025

+0.20 1.39%

ISIN

US8740602052

Symbol

TAK

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$45.6b

Enterprise Value

$73.4b

Net debt

$27.7b

Cash

$2.7b

Shares outstanding

1.6b

Valuation (TTM | estimate)

P/E

31.4 | 14.4

P/S

1.5 | 1.5

EV/Sales

2.4 | 2.4

EV/FCF

15.3

P/B

1.0

Dividends

DPS

$0.67

Yield 1Y | 5Y

4.6% | 4.5%

Growth 1Y | 5Y

8.8% | -4.3%

Payout 1Y | 3Y

144.6% | 78.5%

Increased

1 Year

Financials (TTM | estimate)

Revenue

$30.9b | $31.1b

EBITDA

$6.5b | $8.2b

EBIT

$2.3b | $2.7b

Net Income

$728.7m | $1.6b

Free Cash Flow

$4.8b

Growth (TTM | estimate)

Revenue

7.5% | 0.5%

EBITDA

4.0% | 23.9%

EBIT

-14.0% | 17.3%

Net Income

-25.1% | 116.1%

Free Cash Flow

201.1%

Financial Health

Equity Ratio

48.7%

Return on Equity

1.6%

ROCE

2.9%

ROIC

1.8%

Debt/Equity

0.7

EPS

$0.5

FCF per Share

$3.0

Short interest

0.1%

Employees

49k

Rev per Employee

$630.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

20 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

11x Buy

55%

9x Hold

45%

More details on Analyst Estimates Including Price Targets

20 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

Buy

55%

Hold

45%

Analyst Estimates with Stock Price Targets

Financial data from Takeda Pharmaceutical Co. Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	30,935 30,935	7% 7% 100%
- Direct Costs	10,670 10,670	11% 11% 34%
Gross Profit	20,265 20,265	6% 6% 66%
- Selling and Administrative Expenses	7,459 7,459	5% 5% 24%
- Research and Development Expense	4,930 4,930	0% 0% 16%
EBITDA	6,464 6,464	4% 4% 21%
- Depreciation and Amortization	4,151 4,151	18% 18% 13%
EBIT (Operating Income) EBIT	2,313 2,313	14% 14% 7%
Net Profit	729 729	25% 25% 2%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock News

Neutral

Seeking Alpha

●

13 days ago

Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q1 FY2025 Earnings Call July 30, 2025 6:00 AM ET Company Participants Furuta - Corporate Participant O'Reilly - Corporate Participant Plump - Corporate Participant Weber - Corporate Participant Conference Call Participants Barker - Unidentified Company Kim - Unidentified Company Matsubara - Unidentified Company Muraoka - Unidentified Company Ned...

Neutral

Business Wire

●

14 days ago

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter. The company expects these impacts to moderate in future quarters. Takeda also achieve...

Neutral

Business Wire

●

22 days ago

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHubTM and HyHubTM Duo, devices for patients 17 years of age and older that allow HYQVIA® [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] to be transferred from vials without using a needle in...

More Takeda Pharmaceutical Co. Ltd. Sponsored ADR News

Company Profile

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Head office	Japan
CEO	Christophe Weber
Employees	49,281
Founded	1781
Website	www.takeda.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now